scPharmaceuticals (NASDAQ:SCPH - Get Free Report) will post its quarterly earnings results after the market closes on Tuesday, May 14th. Analysts expect scPharmaceuticals to post earnings of ($0.45) per share for the quarter. Persons that wish to listen to the company's earnings conference call can do so using this link.
scPharmaceuticals (NASDAQ:SCPH - Get Free Report) last announced its quarterly earnings results on Wednesday, March 13th. The company reported ($0.35) earnings per share for the quarter, topping analysts' consensus estimates of ($0.42) by $0.07. scPharmaceuticals had a negative net margin of 403.22% and a negative return on equity of 97.18%. The company had revenue of $6.10 million for the quarter, compared to analysts' expectations of $6.10 million. On average, analysts expect scPharmaceuticals to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.
scPharmaceuticals Trading Down 4.3 %
Shares of SCPH traded down $0.21 during trading hours on Wednesday, reaching $4.69. The stock had a trading volume of 159,416 shares, compared to its average volume of 215,920. The firm has a 50-day moving average of $5.08 and a 200 day moving average of $5.43. The company has a quick ratio of 6.40, a current ratio of 7.08 and a debt-to-equity ratio of 1.04. The company has a market cap of $169.07 million, a P/E ratio of -3.30 and a beta of 0.09. scPharmaceuticals has a 52 week low of $4.25 and a 52 week high of $12.75.
Wall Street Analysts Forecast Growth
Separately, HC Wainwright reaffirmed a "buy" rating and set a $18.00 price target on shares of scPharmaceuticals in a research report on Thursday, March 14th.
View Our Latest Research Report on SCPH
About scPharmaceuticals
(
Get Free Report)
scPharmaceuticals Inc, a pharmaceutical company, engages in the development and commercialization of various pharmaceutical products. Its lead product candidate is FUROSCIX that consists of formulation of furosemide, which is delivered through an on-body infusor for treatment of congestion due to fluid overload in adults with chronic heart failure and kidney disease, as well as consists of subcutaneous loop diuretic that delivers IV equivalent diuresis at home; and FUROSCIX On-Body Infusor, a drug-device combination product consisting of FUROSCIX.
Featured Articles
Before you consider scPharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and scPharmaceuticals wasn't on the list.
While scPharmaceuticals currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.
Get This Free Report
